GAITHERSBURG, Md., Dec. 7 /PRNewswire-FirstCall/ -- MedImmune, Inc. announced today that the Washington Business Journal has recognized Lota Zoth as one of the region's most influential business women at an inaugural "Women Who Mean Business" awards reception held recently in Washington, D.C. Ms. Zoth is the senior vice president and chief financial officer at MedImmune, and is responsible for oversight of finance, information management and corporate communications.
The "Women Who Mean Business" award honors women who have made lasting contributions to Washington business through innovation, outstanding performance and meaningful community involvement. Ms. Zoth was among 49 diverse honorees representing more than a dozen industries ranging from hospitality to biotechnology. The honorees were selected from a pool of more than 200 nominations.
"We are proud that the Washington Business Journal has recognized Lota's outstanding contributions to MedImmune and to the community," said David M. Mott, chief executive officer. "Lota's professional accomplishments, dedication to her work and commitment to the corporate community establish her as an exemplary leader in our company and in the biotechnology industry."
Ms. Zoth was honored for her professional accomplishments and her commitment to community service. At MedImmune, she plays an integral role in broadening the company's professional development initiatives for employees. She encourages professional growth and team-building within the organization and serves as a mentor to her colleagues. Ms. Zoth has spearheaded MedImmune's community relations initiatives including company-wide participation in The Leukemia and Lymphoma Society's "Light the Night" walk and the Salvation Army's annual "Giving Tree" program.
A Texas native, Ms. Zoth is a certified public accountant, and holds a bachelor's of business administration in accounting from Texas Tech University.
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 1,900 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com/.
This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the company's filings with the U.S. Securities and Exchange Commission. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.